account_balance
Investment manager · 13F filer · SEC CIK 1892134
Frazier Life Sciences Management, L.P.
Reported value$4.59Bas of Jun 30, 2026
Positions41 6 new, 3 sold out
Top 10 weight73.6%MIRM alone is 20%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
MIRMMirum Pharmaceuticals Inc
19.6%
NAMSNewamsterdam Pharma Company
13.3%Added +7%
ERASErasca Inc
10.0%
MBXMBX Biosciences Inc
8.0%
ARQTArcutis Biotherapeutics Inc
5.6%
TRVITrevi Therapeutics Inc
4.0%
KRYSKrystal Biotech Inc
3.9%
MAZEMaze Therapeutics Inc
3.3%Added +10%
PHATPhathom Pharmaceuticals Inc
2.9%
PVLAPalvella Therapeutics Inc Ne
2.9%
BBIOBridgebio Pharma Inc
2.5%Trimmed −55%
IRONDisc Medicine Inc
2.2%
MIRMMirum Pharmaceuticals Inc
19.6%
NAMSNewamsterdam Pharma Company
13.3%Added +7%
ERASErasca Inc
10.0%
MBXMBX Biosciences Inc
8.0%
ARQT5.6%TRVI4.0%KRYS3.9%MAZE3.3%PHAT2.9%PVLA2.9%BBIO2.5%IRON2.2%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
MIRM Mirum Pharmaceuticals Inc 19.6% HeldNAMS Newamsterdam Pharma Company 13.3% Added +7%ERAS Erasca Inc 10.0% HeldMBX MBX Biosciences Inc 8.0% HeldARQT Arcutis Biotherapeutics Inc 5.6% HeldTRVI Trevi Therapeutics Inc 4.0% HeldKRYS Krystal Biotech Inc 3.9% HeldMAZE Maze Therapeutics Inc 3.3% Added +10%PHAT Phathom Pharmaceuticals Inc 2.9% HeldPVLA Palvella Therapeutics Inc Ne 2.9% HeldBBIO Bridgebio Pharma Inc 2.5% Trimmed −55%IRON Disc Medicine Inc 2.2% Held
What changed